世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

アルコール性肝炎治療市場(タイプ別と地域別) - 世界の予測と分析 2019-2023年

Alcoholic Hepatitis Treatment Market by Type and Geography - Global Forecast and Analysis 2019-2023

IRTNTR31527

 

出版社 出版年月電子版価格 ページ数
TechNavio
テクナビオ
2019年6月US$2,500
シングルユーザライセンス
114

サマリー

この調査レポートはアルコール性肝炎治療市場を分析・予測したTechNavioの市場調査報告書です。

Overview

Global Alcoholic Hepatitis Treatment Market: About this market

Alcoholic hepatitis is inflammation of the liver, which is caused due to the heavy drinking of alcohol. Technavio’s alcoholic hepatitis treatment market analysis considers sales from different types of treatments, including corticosteroids, xanthine derivatives, and others. Our analysis also considers the sales of alcoholic hepatitis treatment in Asia, Europe, North America, and ROW. In 2018, the corticosteroids segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the development of combination therapies will play a significant role in the corticosteroids segment to maintain its market position. Also, our global alcoholic hepatitis treatment market report looks at factors such as the increasing consumption of alcohol worldwide, availability of prognostic models for alcoholic hepatitis, and high market penetration of corticosteroids and off-label therapies. However, lack of therapies to treat severe alcoholic hepatitis, side effects associated with drugs used to treat alcoholic hepatitis, and availability of alternative therapies may hamper the growth of the alcoholic hepatitis treatment industry over the forecast period.

Global Alcoholic Hepatitis Treatment Market: Overview

Increasing consumption of alcohol worldwide

Heavy alcohol consumption leads to hepatic encephalopathy and high mortality rates. This has created an opportunity for vendors to launch off-label therapies and corticosteroids in the market. The increasing demand for these drugs will lead to the expansion of the global alcoholic hepatitis treatment market at a CAGR of close to 6% during the forecast period.

Development of novel targets and viable treatment options for the management of alcoholic hepatitis

Vendors are heavily investing in the development of novel targets and viable treatment options due to the lack of effective treatments for severe alcoholic hepatitis. Also, certain novel drugs developed by them are under clinical trials. This further creates growth opportunities for vendors, which is expected to have a positive impact on the overall market growth.

For the detailed list of factors that will drive the global alcoholic hepatitis treatment market during the forecast period 2019-2023, click here.

Competitive Landscape

With the presence of a few major players, the global alcoholic hepatitis treatment market is concentrated. Technavio’s robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading alcoholic hepatitis treatment manufacturers, that include Apotex Inc., Gilead Sciences Inc., Johnson & Johnson Services Inc., Novartis AG, and Teva Pharmaceutical Industries Ltd.

Also, the alcoholic hepatitis treatment market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.



目次

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

2.1 Preface

2.2 Preface

2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

Market ecosystem

Market characteristics

Market segmentation analysis

PART 04: MARKET SIZING

Market definition

Market sizing 2018

Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

Bargaining power of buyers

Bargaining power of suppliers

Threat of new entrants

Threat of substitutes

Threat of rivalry

Market condition

PART 06: MARKET SEGMENTATION BY TYPE

Market segmentation by type

Comparison by type

Corticosteroids - Market size and forecast 2018-2023

Xanthine derivatives - Market size and forecast 2018-2023

Others - Market size and forecast 2018-2023

Market opportunity by type

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

Geographic segmentation

Geographic comparison

North America - Market size and forecast 2018-2023

Europe - Market size and forecast 2018-2023

Asia - Market size and forecast 2018-2023

ROW - Market size and forecast 2018-2023

Key leading countries

Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

Market drivers

Market challenges

PART 11: MARKET TRENDS

Development of combination therapies to treat severe alcoholic hepatitis

Development of novel targets and viable treatment options for

management of alcoholic hepatitis

Research for development of drugs that act against alcohol dependence

PART 12: VENDOR LANDSCAPE

Overview

Landscape disruption

PART 13: VENDOR ANALYSIS

Vendors covered

Vendor classification

Market positioning of vendors

Apotex Inc.

Gilead Sciences Inc.

Johnson & Johnson Services Inc.

Novartis AG

Teva Pharmaceutical Industries Ltd.

PART 14: APPENDIX

Research methodology

List of abbreviations

Definition of market positioning of vendors

PART 15: EXPLORE TECHNAVIO

Exhibit 01: Global metabolic disorder therapeutics market

Exhibit 02: Segments of global metabolic disorder therapeutics market

Exhibit 03: Market characteristics

Exhibit 04: Market segments

Exhibit 05: Market definition - Inclusions and exclusions checklist

Exhibit 06: Market size 2018

Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)

Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)

Exhibit 09: Five forces analysis 2018

Exhibit 10: Five forces analysis 2023

Exhibit 11: Bargaining power of buyers

Exhibit 12: Bargaining power of suppliers

Exhibit 13: Threat of new entrants

Exhibit 14: Threat of substitutes

Exhibit 15: Threat of rivalry

Exhibit 16: Market condition - Five forces 2018

Exhibit 17: Type - Market share 2018-2023 (%)

Exhibit 18: Comparison by type

Exhibit 19: Corticosteroids - Market size and forecast 2018-2023 ($ millions)

Exhibit 20: Corticosteroids - Year-over-year growth 2019-2023 (%)

Exhibit 21: Xanthine derivatives - Market size and forecast 2018-2023 ($ millions)

Exhibit 22: Xanthine derivatives - Year-over-year growth 2019-2023 (%)

Exhibit 23: Others - Market size and forecast 2018-2023 ($ millions)

Exhibit 24: Others - Year-over-year growth 2019-2023 (%)

Exhibit 25: Market opportunity by type

Exhibit 26: Customer landscape

Exhibit 27: Market share by geography 2018-2023 (%)

Exhibit 28: Geographic comparison

Exhibit 29: North America - Market size and forecast 2018-2023 ($ millions)

Exhibit 30: North America - Year-over-year growth 2019-2023 (%)

Exhibit 31: Europe - Market size and forecast 2018-2023 ($ millions)

Exhibit 32: Europe - Year-over-year growth 2019-2023 (%)

Exhibit 33: Asia - Market size and forecast 2018-2023 ($ millions)

Exhibit 34: Asia - Year-over-year growth 2019-2023 (%)

Exhibit 35: ROW - Market size and forecast 2018-2023 ($ millions)

Exhibit 36: ROW - Year-over-year growth 2019-2023 (%)

Exhibit 37: Key leading countries

Exhibit 38: Market opportunity

Exhibit 39: Impact of drivers and challenges

Exhibit 40: Novel drugs under development for alcoholic hepatitis

Exhibit 41: Vendor landscape

Exhibit 42: Landscape disruption

Exhibit 43: Vendors covered

Exhibit 44: Vendor classification

Exhibit 45: Market positioning of vendors

Exhibit 46: Apotex Inc. - Vendor overview

Exhibit 47: Apotex Inc. - Key offerings

Exhibit 48: Gilead Sciences Inc. - Vendor overview

Exhibit 49: Gilead Sciences Inc. - Business segments

Exhibit 50: Gilead Sciences Inc. - Organizational developments

Exhibit 51: Gilead Sciences Inc. - Geographic focus

Exhibit 52: Gilead Sciences Inc. - Key offerings

Exhibit 53: Johnson & Johnson Services, Inc. - Vendor overview

Exhibit 54: Johnson & Johnson Services, Inc. - Business segments

Exhibit 55: Johnson & Johnson Services, Inc. - Organizational developments

Exhibit 56: Johnson & Johnson Services, Inc. - Geographic focus

Exhibit 57: Johnson & Johnson Services, Inc. - Segment focus

Exhibit 58: Johnson & Johnson Services, Inc. - Key offerings

Exhibit 59: Novartis AG - Vendor overview

Exhibit 60: Novartis AG - Business segments

Exhibit 61: Novartis AG - Organizational developments

Exhibit 62: Novartis AG - Geographic focus

Exhibit 63: Novartis AG - Segment focus

Exhibit 64: Novartis AG - Key offerings

Exhibit 65: Teva Pharmaceutical Industries Ltd. - Vendor overview

Exhibit 66: Teva Pharmaceutical Industries Ltd. - Business segments

Exhibit 67: Teva Pharmaceutical Industries Ltd. - Organizational developments

Exhibit 68: Teva Pharmaceutical Industries Ltd. - Segment focus

Exhibit 69: Teva Pharmaceutical Industries Ltd. - Key offerings

Exhibit 70: Validation techniques employed for market sizing

Exhibit 71: Definition of market positioning of vendors

 

ページTOPに戻る

あなたが最近チェックしたレポート一覧

  • 最近チェックしたレポートはありません。

お問合は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのお問合せはこちらのフォームから承ります

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

<無料>メルマガに登録する

 

 

ページTOPに戻る